- Home
- LUCD vs TNXP Comparison
LUCD vs TNXP Comparison
Compare LUCD & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUCD
- TNXP
- Stock Information
- Founded
- LUCD 2018
- TNXP 2007
- Country
- LUCD United States
- TNXP United States
- Employees
- LUCD 70
- TNXP N/A
- Industry
- LUCD Biotechnology: Electromedical & Electrotherapeutic Apparatus
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- LUCD Health Care
- TNXP Health Care
- Exchange
- LUCD Nasdaq
- TNXP Nasdaq
- Market Cap
- LUCD 135.6M
- TNXP 118.2M
- IPO Year
- LUCD 2021
- TNXP N/A
- Fundamental
- Price
- LUCD $1.19
- TNXP $18.94
- Analyst Decision
- LUCD Strong Buy
- TNXP Strong Buy
- Analyst Count
- LUCD 4
- TNXP 2
- Target Price
- LUCD $3.88
- TNXP $585.00
- AVG Volume (30 Days)
- LUCD 1.3M
- TNXP 590.0K
- Earning Date
- LUCD 05-14-2025
- TNXP 05-20-2025
- Dividend Yield
- LUCD N/A
- TNXP N/A
- EPS Growth
- LUCD N/A
- TNXP N/A
- EPS
- LUCD N/A
- TNXP N/A
- Revenue
- LUCD $4,346,000.00
- TNXP $10,094,000.00
- Revenue This Year
- LUCD $107.75
- TNXP $12.17
- Revenue Next Year
- LUCD $231.37
- TNXP $789.15
- P/E Ratio
- LUCD N/A
- TNXP N/A
- Revenue Growth
- LUCD 79.00
- TNXP 29.94
- 52 Week Low
- LUCD $0.63
- TNXP $6.76
- 52 Week High
- LUCD $1.80
- TNXP $672.00
- Technical
- Relative Strength Index (RSI)
- LUCD 40.89
- TNXP 53.83
- Support Level
- LUCD $1.19
- TNXP $18.55
- Resistance Level
- LUCD $1.24
- TNXP $21.99
- Average True Range (ATR)
- LUCD 0.07
- TNXP 1.51
- MACD
- LUCD -0.00
- TNXP 0.27
- Stochastic Oscillator
- LUCD 10.53
- TNXP 60.18
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.